Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $110.00 | 1 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Advanced Accelerator Applications | $110.00 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $110.00 | 1 | Advanced Accelerator Applications ($110.00) |
All Payment Transactions
1 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/23/2019 | Advanced Accelerator Applications | Lutathera (Drug) | Food and Beverage | In-kind items and services | $110.00 | General |
| Category: Radioactive targeted therapy - Neuroendocrine tumors | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 525 | 531 | $1.3M | $431,963 |
| 2022 | 4 | 782 | 893 | $2.0M | $701,201 |
| 2021 | 3 | 375 | 383 | $826,571 | $313,558 |
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 227 | 229 | $917,374 | $275,976 | 30.1% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 256 | 259 | $176,120 | $103,761 | 58.9% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 42 | 43 | $172,301 | $52,226 | 30.3% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2022 | 325 | 334 | $1.3M | $411,152 | 30.8% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2022 | 377 | 387 | $263,160 | $156,240 | 59.4% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2022 | 69 | 71 | $284,497 | $88,035 | 30.9% |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | Office | 2022 | 11 | 101 | $168,203 | $45,774 | 27.2% |
| 78815 | Nuclear medicine study with ct imaging skull base to mid-thigh | Office | 2021 | 172 | 176 | $621,060 | $214,926 | 34.6% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2021 | 186 | 190 | $129,200 | $77,672 | 60.1% |
| 78816 | Nuclear medicine study with ct imaging whole body | Office | 2021 | 17 | 17 | $76,311 | $20,960 | 27.5% |
About Dr. Mary Hart, MD
Dr. Mary Hart, MD is a Nuclear Radiology healthcare provider based in Orlando, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164437455.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mary Hart, MD has received a total of $110.00 in payments from pharmaceutical and medical device companies, with $110.00 received in 2019. These payments were reported across 1 transactions from 1 company. The most common payment nature is "Food and Beverage" ($110.00).
As a Medicare-enrolled provider, Hart has provided services to 1,682 Medicare beneficiaries, totaling 1,807 services with total Medicare billing of $1.4M. Data is available for 3 years (2021–2023), covering 10 distinct procedure/service records.
Practice Information
- Specialty Nuclear Radiology
- Other Specialties Diagnostic Radiology, Therapeutic Radiology
- Location Orlando, FL
- Active Since 07/29/2006
- Last Updated 06/21/2010
- Taxonomy Code 2085N0904X
- Entity Type Individual
- NPI Number 1164437455
Products in Payments
- Lutathera (Drug) $110.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.